← Back to Screener
Vivos Therapeutics, Inc. Common Stock (VVOS)
Price$0.86
Value ScoreB
Growth ScoreB
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-69.67%
Price vs S&P 500 (4W)30.05%
VGM Score54.56
Market Capitalization$8.94M
All Metrics
Book Value / Share (Quarterly)$0.31
P/TBV (Annual)3.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.88%
Cash Flow / Share (Quarterly)$-1.46
Price vs S&P 500 (YTD)-65.57%
Gross Margin (TTM)61.80%
Net Profit Margin (TTM)-127.70%
EPS (TTM)$-2.12
10-Day Avg Trading Volume7.13M
EPS Excl Extra (TTM)$-2.12
Revenue Growth (5Y)5.94%
EPS (Annual)$-2.06
ROI (Annual)-140.01%
Gross Margin (Annual)60.44%
Net Profit Margin (5Y Avg)-112.58%
Cash / Share (Quarterly)$0.16
Revenue Growth QoQ (YoY)70.46%
ROA (Last FY)-84.17%
Revenue Growth TTM (YoY)33.77%
EBITD / Share (TTM)$-1.78
ROE (5Y Avg)-818.50%
Operating Margin (TTM)-115.47%
Cash Flow / Share (Annual)$-1.90
P/B Ratio3.53x
P/B Ratio (Quarterly)10.12x
Net Income / Employee (Annual)$-79,000
EV / Revenue (TTM)0.75x
Net Interest Coverage (TTM)-14.16x
ROA (TTM)-98.12%
EPS Incl Extra (Annual)$-2.06
Current Ratio (Annual)0.24x
Quick Ratio (Quarterly)0.22x
3-Month Avg Trading Volume0.97M
52-Week Price Return-60.88%
Revenue / Employee (TTM)$73,000
Tangible BV / Share (Quarterly)$0.04
P/S Ratio (Annual)0.51x
Asset Turnover (Annual)0.69x
52-Week High$7.95
Operating Margin (5Y Avg)-116.51%
EPS Excl Extra (Annual)$-2.06
CapEx CAGR (5Y)81.15%
26-Week Price Return-61.75%
Quick Ratio (Annual)0.20x
13-Week Price Return-37.36%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.27x
Enterprise Value$14.70M
Revenue / Share Growth (5Y)-37.57%
Asset Turnover (TTM)0.77x
Revenue / Employee (Annual)$65,100
Pretax Margin (Annual)-121.71%
Cash / Share (Annual)$0.22
3-Month Return Std Dev104.93%
Gross Margin (5Y Avg)63.50%
Net Income / Employee (TTM)$-93,200
ROE (Last FY)-140.01%
Net Interest Coverage (Annual)-11.40x
EPS Basic Excl Extra (Annual)$-2.06
Receivables Turnover (TTM)15.74x
Total Debt / Equity (Quarterly)3.51x
EPS Incl Extra (TTM)$-2.12
Receivables Turnover (Annual)17.35x
ROI (TTM)-187.51%
P/S Ratio (TTM)0.46x
Pretax Margin (5Y Avg)-112.65%
Revenue / Share (Annual)$1.70
Tangible BV / Share (Annual)$1.29
Price vs S&P 500 (52W)-85.25%
Year-to-Date Return-57.41%
5-Day Price Return26.20%
EPS Normalized (Annual)$-2.06
ROA (5Y Avg)-103.54%
Net Profit Margin (Annual)-121.37%
Month-to-Date Return23.50%
Cash Flow / Share (TTM)$-13.48
EBITD / Share (Annual)$-1.81
Operating Margin (Annual)-114.05%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-816.53%
LT Debt / Equity (Quarterly)3.31x
EPS Basic Excl Extra (TTM)$-2.12
P/TBV (Quarterly)71.19x
P/B Ratio (Annual)3.18x
Pretax Margin (TTM)-128.36%
Book Value / Share (Annual)$1.35
Price vs S&P 500 (13W)-45.61%
Beta6.16x
Revenue / Share (TTM)$1.34
ROE (TTM)-351.28%
52-Week Low$0.55
vGradeB
gGradeB
mGradeF
vgmGradeC
Show chart for
Earnings Surprise History
Q4 25-0.58est. -0.49
Q1 26-0.52est. -0.46
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VVOSVivos Therapeutics, Inc. Common Stock | B | B | F | $0.86 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Vivos Therapeutics develops a non-invasive oral appliance system for treating mild-to-moderate obstructive sleep apnea, combining customized devices with proprietary clinical protocols. The approach offers patients a lower-cost alternative to surgery or pharmaceuticals. The therapy is delivered through a network of specially trained dentists working with medical professionals, creating a differentiated market position in sleep disorder treatment.